De Novo Acute Heart Failure and Acutely Decompensated Chronic Heart Failure
; ; ;
Background: Heart failure is one of the most common diseases of adults in Europe, with an overall prevalence of 1–2%. Among persons aged 60 and above, its prevalence is above 10% in men and 8% in women. Acute heart failure has a poor prognosis; it is associated with a high rate of rehospitalization and a 1-year mortality of 20–30%.
Methods: This review is based on pertinent literature, including guidelines, retrieved by a selective search in PubMed.
Results: There are different types of acute heart failure; the basic diagnostic assessment is performed at once and consists of ECG, echocardiography, and the measurement of N-terminal pro-brain natriuretic peptide (NTproBNP) and troponin levels. The most common causes of decompensation are arrhythmia, valvular dysfunction, and acute cardiac ischemia, each of which accounts for 30% of cases. The potential indication for immediate revascularization should be carefully considered in cases where acute heart failure is due to coronary heart disease. The basic treatment of acute heart failure is symptomatic, with the administration of oxygen, diuretics, and vasodilators. Ino-tropic agents, vasopressors, and temporary mechanical support for the circulatory system are only used to treat cardiogenic shock.
Conclusion: The treatment of acute heart failure is markedly less evidence-based than that of chronic heart failure. Newer treatment approaches that are intended to improve outcomes still need to be tested in multicenter trials.
Heart failure (or congestive heart failure, as it is often called in the English-speaking countries) has an overall prevalence of 1–2% and is thus one of the most common diseases affecting adults in Europe today (1). In Germany, it is the most common main diagnosis leading to hospitalization (2). Its prevalence is under 0.5% in persons aged 20 to 40, but much higher in persons over age 60 (more than 10% in men, more than 8% in women) (2, 3). In recent years, the introduction of drug therapy with beneficial long-term effects (e1–e4), implantable defibrillators (e5), and cardiac resynchronization systems (e6) has lessened the 5-year mortality of chronic heart failure, which was previously more than 75% in men and about 60% in women (4). In contrast, there has been essentially no improvement in the prognosis of patients with acute heart failure. The in-hospital mortality of this condition was about 7% in the EuroHeart Failure Survey II, albeit with marked differences depending on the clinical type of acute heart failure (Figure 1) (5). The 1-year mortality was 20–30%; patients with de novo acute heart failure fared somewhat better than those with acutely decompensated chronic heart failure (ADCHF) (6).
This article should enable readers to:
- know the epidemiology and pathogenesis of acute heart failure
- know, and apply knowledge of, the main symptoms and signs of acute heart failure, and the relevant diagnostic tests
- be familiar with the treatments of acute and acutely decompensated chronic heart failure.
This review is based on pertinent literature retrieved by a selective search in PubMed up to October 2014, including the guidelines of the European Society of Cardiology and the German Cardiac Society.
The definition of acute and chronic heart failure
Heart failure is defined pathophysiologically as the inability of the heart to supply the body’s tissues with an adequate amount of blood under conditions of normal cardiac filling pressure (7).
Acute and chronic heart failure differ both in their temporal course and in their treatment.
Acute heart failure has two forms: newly arisen (“de novo”) acute heart failure and acutely decompensated chronic heart failure (ADCHF). According to the EuroHeart Failure Survey II (5), two-thirds of all patients admitted to a hospital with acute heart failure already have a known history of heart failure.
The events precipitating acute decompensation mainly consisted of arrhythmias, valvular dysfunction, and acute cardiac ischemia, each of which accounted for about 30% of cases. Further precipitating factors are listed in Box 1.
The subtype of heart failure known as “heart failure with reduced ejection fraction” (HF-REF) is characterized by left-ventricular dilatation (ventricular remodeling) and a reduction of the left-ventricular ejection fraction (LVEF) below 40%. In contrast, “heart failure with preserved ejection fraction” (HF-PEF, diastolic heart failure) is characterized by normal left-ventricular volume and ejection fraction (LVEF >50%), although the thickness of the ventricular wall and the ratio of left-ventricular mass to end-diastolic volume is increased, as is the stiffness of the myocardium. Despite the structural and functional differences between HF-REF and HF-PEF, decompensated heart failure of either type displays the same pathophysiologic mechanisms, i,e., rising cardiac filling pressures and diminished intrinsic contractility of cardiac myocytes (3). Often, about two weeks before acute decompensation, backward failure of the left ventricle arises, resulting in pulmonary congestion (Figure 2) (8, 9). Sodium and fluid retention are major components of the clinical picture of heart failure, causing shortness of breath and peripheral edema. Cardiac and renal function are linked; the treatment of heart failure with diuretics and the recommendation for salt restriction are based on this close relationship.
The neuroendocrine system plays a key role in the progression of heart failure. In order to keep the vital organs adequately perfused, the sympathetic nervous system is activated, leading to increased myocardial contractility. Prolonged activation of the adrenergic system and the renin-angiotensin-aldosterone (RAA) system impairs ventricular remodeling and leads to the destruction of myocardial tissue by apoptosis. Activation of the RAA system also leads to myocardial fibrosis, which increases the stiffness of the myocardium and impairs left-ventricular relaxation in diastole. Pharmacologic blockade of the adrenergic and RAA systems can improve the survival of patients with chronic heart failure; this clearly indicates the central importance of the neuroendocrine system in the treatment of heart failure (3). The clinical presentations of acute heart failure are delineated in Figure 3.
Clinical features and diagnostic assessment
According to data from the ADHERE registry (10), 89% of patients hospitalized for acute heart failure complain on admission of shortness of breath; 68% have pulmonary crackles and 66% have peripheral edema, indicating the retrograde effects of impaired left-ventricular pump function, with increased amounts of blood in the pulmonary vessels and in the peripheral veins. Further typical findings include pleural effusions, a third heart sound, tachycardia, and congested neck veins (e8). The patient’s past medical history should be carefully considered, including the chronology of the onset of symptoms, any already diagnosed cardiac illness, and precipitating factors (Box 1).
The most important physical findings are peripheral edema and abnormalities of the heart and lungs. A heart murmur may indicate a significant valvular problem. Percussion and auscultation of the chest may arouse suspicion of a large pleural effusion, pulmonary congestion, or pulmonary edema.
The differential diagnostic evaluation of shortness of breath in suspected acute heart failure includes an ECG and a chest x-ray as basic tests, as well as two further investigations: echocardiography and measurement of the natriuretic peptides pro-brain natriuretic peptide (BNP) and/or NT-proBNP (Figure 4). The blood pressure, heart rate and rhythm, peripheral oxygenation, and urine excretion should be closely monitored and the measured values documented at frequent intervals. Immediate diagnostic evaluation enables the recognition of precipitating factors that may require treatment without delay (e.g., arrhythmias, a hypertensive crisis, or an acute coronary syndrome) and the early initiation of treatment to stabilize hemodynamic and respiratory function.
Echocardiography is the main imaging study and a standard test in all patients with suspected acute heart failure. It can detect severe valvular dysfunction or a pericardial effusion and can be used to assess the size of the cardiac ventricles and atria. In particular, it enables both global and local evaluation of left-ventricular function. A left-ventricular ejection fraction under 35% indicates heart failure with reduced left-ventricular systolic function (HF-REF).
The quotient of early-diastolic flow across the mitral valve to relaxation of the mitral ring (E/A ratio) can be determined by Doppler echocardiography and may indicate elevated left-ventricular end-diastolic pressure (e8).
Natriuretic peptide levels that are in the reference range (i.e., below the cutoff points of 100 pg/mL BNP or 300 pg/mL NT-proBNP), in a patient who has not yet received treatment, effectively rule out heart failure as the cause of symptoms (high negative predictive value) (7). Values above the reference range indicate probable heart failure, but other causes of shortness of breath must also be considered. A second determination of a BNP/NT-proBNP level on discharge can enable better prediction of the risk of rehospitalization and of 1-year mortality (e9): if the BNP/NT-proBNP level declines by less than 50%, the risk of rehospitalization or death within 12 months is elevated by 40% (e10).
The myocardium-specific troponin levels may be mildly elevated in acute, or severe chronic, heart failure. This is prognostically significant: patients in the ADHERE registry with acute heart failure who had elevated troponin levels had a markedly higher in-hospital mortality than those with normal troponin levels (8.0% vs. 2.7%, p<0.001) (10). Myocardial troponin release is thought to be due to direct injury to cardiac myocytes as a result of cardiac decompensation (12). Depending on the patient’s symptoms and signs and, in particular, on the time course of the myocardium-specific troponin levels, an acute coronary syndrome may have to be considered as a possible cause of acute heart failure, and then treated as necessary.
To identify other possible causes of the clinical manifestations, renal function parameters and the serum albumin, hemoglobin, electrolyte, and thyroid-stimulating hormone levels should be measured in all patients with suspected heart failure.
The goals of treating acute heart failure are
- to improve symptoms,
- to achieve hemodynamic stability,
- to prevent recurrent heart failure, and
- to reduce mortality.
The patients at highest risk of dying as a consequence of acute heart failure (elderly patients and those with a low systolic blood pressure, renal dysfunction, signs of peripheral hypoperfusion, and acute coronary syndrome ) should be monitored and treated on an intensive care unit (Figure 5).
The treatment of acute heart failure is markedly less evidence-based than that of chronic heart failure with reduced ejection fraction (HF-REF). In the following sections, treatment recommendations are accompanied by recommendation grades from the guideline of the European Society of Cardiology (7).
Acute coronary angiography and revascularization
Acute coronary syndrome accounts for 11% of cases of de novo acute heart failure (infarct with ST-segment elevation) and one-third of all cases of acutely decompensated chronic heart failure (5). Acute coronary syndrome with heart failure is an indication for immediate angiographic evaluation and revascularization (grade I recommendation, level A evidence) (13).
The Shock Trial led to the finding that rapid revascularization in cases of cardiogenic shock was associated with a 67% (relative) reduction in mortality that persisted over six years (14). It is currently being investigated whether the revascularization of all high-grade coronary artery stenoses in patients with cardiogenic shock confers an advantage with respect to survival compared to the revascularization only of the vessel responsible for the infarct (CULPRIT-SHOCK, NCT 01927549). Patients who undergo coronary angiography and (if indicated) revascularization during their first hospitalization for de novo acute heart failure have a significantly lower mortality and rehospitalization rate (15).
Oxygen administration and non-invasive vs. invasive ventilation
Patients with hypoxemia (oxygen saturation below 90% by pulse oximetry) should be given supplemental oxygen (grade I recommendation, level C evidence). The goal is to raise the arterial oxygen saturation to at least 95%. In patients who also suffer from chronic obstructive pulmonary disease, the risk of hypercapnia under oxygen therapy must be borne in mind.
Persistent hypoxemia and/or a respiratory rate above 20/min despite drug treatment and oxygen administration for pulmonary edema should be treated initially with non-invasive ventilation (grade IIa recommendation, level B evidence). Meta-analyses have shown that this lowers mortality by 37–45% compared to the standard treatment of acute pulmonary edema (16, e11). Invasive ventilation is recommended for patients who show signs of respiratory exhaustion or are in cardiac shock, or whose consciousness is impaired.
Analgesia and sedation
Opioids are helpful for patients who are agitated because of anxiety and dyspnea; they should be given cautiously, with continuous monitoring of the peripheral oxygen saturation and the frequency and depth of breathing (grade IIa recommendation, level C evidence). Opioid administration for patients with pulmonary edema seems reasonable for pathophysiological reasons, as opioids are vasodilators that lessen preload.
Diuretics and ultrafiltration
Diuretics are commonly given to patients in heart failure and have a beneficial effect on symptoms (grade I recommendation, level B evidence); their clinically evident utility is pathophysiologically explicable by the reduction of pulmonary congestion, but a putative improvement in outcome through the use of diuretics has not yet been well documented in prospective trials (17). In particular, the optimal dose, mechanism of action, and mode of administration (oral, intravenous bolus, or continuous infusion) remain unclear. Intravenous loop diuretics should be given to treat acute decompensation because of their faster effect and the independence of their uptake from gastrointestinal resorption, which is unreliable in the setting of right-heart decompensation (18). The DOSE trial was the first to investigate the dosage of loop diuretics in acute heart failure; it did not reveal any significant difference between furosemide boli every twelve hours and a continuous infusion of the drug, or between a low and a high dose of furosemide, with respect to either symptomatic improvement or the worsening of renal failure if present (17). The higher diuretic dose was found to be superior with respect to secondary endpoints (improvement of dyspnea, negative fluid balance, weight loss) and had fewer serious side effects, although it more often led to a transient worsening of renal failure. For persistent (diuretic-resistant) edema, a combination of two diuretics with different mechanisms of action has been found useful (a loop diuretic combined with a Na+/Cl–-cotransport inhibitor for sequential nephron blockade) (19). This potent combination may, however, cause hypokalemia, renal failure, and excessive fluid loss. No prospective trials of this mode of treatment are yet available.
Aside from diuretic resistance, it is thought that long-term treatment with diuretics might increase morbidity and mortality, by way of neurohormonal activation, electrolyte disturbances, or worsening of renal failure. The acute cardiorenal syndrome (type 1), defined as a worsening of renal function in patients with acutely decompensated heart failure, arises in 25–33% of patients with ADCHF (20). To determine the appropriate treatment, patients with this syndrome should be classified on pathophysiologic grounds as suffering from either prerenal renal failure with predominant left-heart failure (forward failure) or intrarenal renal failure due to renal venous congestion (backward failure) (20, 21).
In the UNLOAD trial, patients with more than two signs of volume overload were treated for 48 hours with either intravenous diuretics or ultrafiltration (22). Ultrafiltration led to a greater loss of volume and weight with a comparable improvement of dyspnea. There was no significant difference in the rise of creatinine concentration in the two groups. The patients in the ultrafiltration group needed fewer rehospitalizations for heart failure. The much-criticized CARRESS heart failure trial (23, e12) did not confirm these findings in patients with acutely decompensated chronic heart failure and worsening renal failure in the twelve weeks before, and the first ten days after, hospital admission for acutely decompensated chronic heart failure. Metra et al. showed that creatinine elevation is not, in itself, an unfavorable prognostic factor in acutely decompensated chronic heart failure (24). In the ESCAPE trial, for example, patients with higher creatinine values or hemoconcentration during the recompensation phase actually had a higher 180-day survival (25). Higher mortality, and a higher risk of rehospitalization, were associated only with worsening of renal failure with the simultaneous persistence of signs of congestion (24). The current indications for ultrafiltration and renal replacement techniques are listed in Box 2.
Vasodilators lower the systolic blood pressure and should therefore only be used in normotensive patients (systolic blood pressure above 110 mm Hg). In particular, nitroglycerin and sodium nitroprusside can be used to treat pulmonary edema in the presence of hypertension (grade IIa, resp. IIb recommendation, level B evidence). Nitroglycerin lowers pulmonary capillary pressure by lessening cardiac preload. It is relatively contraindicated in patients with severe aortic or mitral stenosis. Sodium nitroprusside lowers cardiac preload and afterload; the dose should be titrated slowly, and only in conjunction with invasive blood pressure monitoring.
Cotter et al, in a randomized trial on 110 patients with severe pulmonary edema in the setting of acutely decompensated chronic heart failure (26), found that a high nitrate dose combined with a low diuretic dose yielded better effects than the reverse, with respect to both oxygen saturation and the rate of mechanical ventilation and/or myocardial infarction (reduction of the latter endpoints from 46% to 25%).
The current recommendations of the European Society of Cardiology (ESC) regarding the use of nitrates in acute heart failure are based on this trial alone.
Inotropic drugs and vasopressors
Patients with refractory hypotension (cardiogenic shock) can be treated with inotropic agents such as dobutamine (grade IIa recommendation, level C evidence). The common side effects of inotropic agents are sinus tachycardia, arrhythmia, and myocardial ischemia. If inotropic agents are ineffective, vasopressors are recommended, above all norepinephrine (grade IIb recommendation, level C evidence). Increased left-ventricular afterload is a common side effect.
Milrinone, a phosphodiesterase-3 inhibitor, was studied as a putative treatment for chronic heart failure in the OPTIME-CHF trial; it was found that milrinone neither improved symptoms nor shortened the hospital stay, but was associated with higher rates of cardiac arrhythmias and hypotension (e13). Milrinone and dobutamine may also increase mortality (27); thus, they should be given as briefly as possible and in the lowest effective dose (grade IIb recommendation, level C evidence).
The calcium-sensitizer levosimendan has been approved for use in Germany and a number of other countries, but not in the USA. It increases myocardial contractility by sensitizing the contractile proteins to calcium, while simultaneously exerting a vasodilating effect by blocking the ATP-dependent calcium channels of vascular smooth muscle. In the REVIVE-I and REVIVE-II trials, patients with acute heart failure who were given a levosimendan infusion for 24 hours in addition to standard treatment experienced a rapid improvement of symptoms with persistent lowering of natriuretic peptide levels, but with a tendency toward symptomatic hypotension and cardiac arrhythmia (28).
The SURVIVE trial revealed no lowering of overall mortality at 180 days through the use of levosimendan (compared to dobutamine), despite a significant acute lowering of natriuretic peptide levels (29). The only evidence to date that levosimendan lowers the mortality of cardiac patients comes from meta-analyses (30).
The use of levosimendan is recommended when there is suspicion that chronic beta-blockade is worsening hypotension in cardiogenic shock and lessening the responsiveness to vasopressor drugs (grade IIb recommendation, level C evidence).
Multi-organ system failure is the most important predictor of death from cardiogenic shock (13). Accordingly, the prevention and treatment of multi-organ system failure in the intensive care unit has a significant effect on survival (13, e14).
Cardiac glycosides have a positive inotropic effect. Their use in the treatment of acute heart failure is limited to the treatment of absolute tachycardia in atrial fibrillation; in this situation, the negative chronotropic effect of cardiac glycosides inhibits atrioventricular conduction (grade I recommendation, level C evidence). In atrial fibrillation with tachycardia and hemodynamic compromise, electrical cardioversion should be considered (grade I recommendation, level C evidence).
Dronedarone and class I antiarrhythmic drugs are contraindicated in acute heart failure (grade III recommendation, level A evidence). Only amiodarone can be used for the purpose of non-urgent pharmacological cardioversion (grade I recommendation, level C evidence).
Mechanical support of the circulation
If cardiogenic shock persists despite optimization of the patient’s volume status and treatment with inotropic drugs and vasopressors, and if it is considered to be potentially reversible, a reasonable treatment option is transient mechanical support of the circulatory system (hours to 30 days) with a microaxial pump in the left ventricle or a minimalized heart-lung machine (extracorporeal membrane oxygenation, ECMO). Such temporary measures serve as a “bridge to recovery” (grade IIa recommendation, level C evidence). The only application of mechanical circulatory support that has been tested in randomized trials is the use of an intra-aortic balloon pump (IABP) to treat cardiogenic shock due to myocardial infarction. Although this has been a standard treatment for many years, the IABP-Shock-II trial showed in 2012 that it did not reduce mortality (31).
Various new treatment approaches have been proposed in recent years with the aim of improving the outcome of patients with acute heart failure, but a better outcome has not been documented in any of the clinical trials carried out to date (Table), nor did any of the treatments lessen the rehospitalization rate.
The only recent trial of a drug for acute heart failure that revealed a benefit of any kind was the RELAX trial, in which the administration of serelaxin (recombinant human relaxin-2, a peptide of pregnancy) was found to result in more rapid relief of symptoms, but did not lower the rate of rehospitalization (37). The hemodynamic effect of serelaxin is to lower both the pulmonary capillary and pulmonary arterial pressure and the pulmonary and systemic vascular resistance, without raising the cardiac index (40). Hypotension was found to be more common under treatment with serelaxin than with placebo (ca. 4–6 mm Hg). The RELAX trial was an acute trial involving a 48-hour infusion of serelaxin starting on admission to the hospital. Interestingly, the 180-day mortality of patients treated with serelaxin was 37% lower than that of those who were given a placebo (4% absolute risk reduction); although 180-day mortality was not a predefined secondary endpoint, this was found in a protocol-specified additional efficacy analysis. The finding is now being followed up in a trial on over 6000 patients, which ought to have sufficient power to document improved survival if this is, in fact, the case (RELAX-AHF-2, NCT01870778).
Prevention of thromboembolism
During the cardiac recompensation phase, and for as long as the patient is confined to bed, a prophylactic drug against thromboembolism should be given, e.g., a low-molecular-weight heparin (grade I recommendation, level A evidence). Atrial fibrillation is an indication for full anticoagulation (grade I recommendation, level A evidence).
The transition to chronic heart failure— further treatment
Once the patient with acute heart failure or acutely decompensated chronic heart failure has become stable, the question of further treatment of the cause of the condition should be addressed. Drug treatment for chronic heart failure should be prescribed on discharge in accordance with the guidelines, and follow-up appointments should be scheduled so that the effects of the medications can be monitored and their doses adjusted as needed.
Conflict of interest statement
Dr. Empen has served as a paid consultant for Novartis and has received honoraria from Novartis for preparing continuing medical education events.
Prof. Felix has served as a paid consultant for Novartis and Cardioventris. He has received reimbursement of congress participation fees and lecture honoraria relating to continuing medical education events from Novartis, Bayer, Berlin Chemie, Cardioventis, and Servier. He has received honoraria in a third-party account for carrying out clinical studies relating to the topic of this article, as well as financial support for a research project that he initiated, from Bayer, Novartis, and Medtronic.
Prof. Dörr and Dr. Hummel state that they have no conflict of interest.
Manuscript received on 18 July 2014; revised version accepted on
17 December 2014.
Translated from the original German by Ethan Taub, M.D.
Prof. Dr. med. Stephan B. Felix
Klinik und Poliklinik für Innere Medizin B
D-17475 Greifswald, Germany
@For eReferences please refer to:
Dr. med. Hummel, PD Dr. med. Empen, Prof. Dr. med. Dörr, Prof. Dr. med. Felix
|1.||Mosterd A, Hoes AW: Clinical epidemiology of heart failure. Heart 2007; 93: 1137–46 CrossRef MEDLINE PubMed Central|
|2.||Neumann T, Biermann J, Neumann A, et al.: Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspective. Dtsch Arztebl Int 2009; 106: 269–75 VOLLTEXT|
|3.||Braunwald, E: Heart failure. J Am Coll Cardiol HF 2013; 1: 1–20 CrossRefMEDLINE|
|4.||Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D: Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107–15 CrossRef|
|5.||Nieminen MS, Brutsaert D, Dickstein K, et al.: EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725–36 CrossRef MEDLINE|
|6.||Harjola VP, Follath F, Nieminen MS, et al.: Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail 2010; 12: 239–48 CrossRef MEDLINE|
|7.||McMurray JJ, Adamopoulos S, Anker SD, et al.: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–847 CrossRef MEDLINE|
|8.||Zile MR, Bennett TD, Sutton MSJ, et al.: Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008; 118: 1433–41 CrossRef MEDLINE|
|9.||Gheorghiade M, Follath F, Ponikowski P, et al.: Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010; 12: 423–33 CrossRef MEDLINE|
|10.||Adams KF Jr., Fonarow GC, Emerman CL, et al.: Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209–16 CrossRef MEDLINE|
|11.||Peacock WF, De Marco T, Fonarow GC, et al.: Cardiac troponin and outcome in acute heart failure. New Engl J Med 2008; 358: 2117–26 CrossRef MEDLINE|
|12.||Kociol RD, Pang PS, Gheorghiade M, et al.: Troponin elevation in heart failure. J Am Coll Cardiol 2010; 56: 1071–78 CrossRef MEDLINE|
|13.||Pöss J, Vollert JO, Böhm M, et al.: Infarktbedingter kardiogener Schock. Kardiologe 2014; 8: 302–12 CrossRef|
|14.||Hochman JS, Sleeper LA, Webb JG, et al.: Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295: 2511–5 CrossRef MEDLINE PubMed Central|
|15.||Flaherty JD, Rossie JS, Fonarow GC, et al.: Influence of coronary angiography on the utilization of therapies in patients with acute heart failure syndromes: Findings from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Am Heart J 2009; 157: 1018–25 CrossRef MEDLINE|
|16.||Mariani J, Macchia, A., Belzeti C, et al.: Noninvasive ventilation in acute cardiogenic pulmonary Eedema: A meta-analysis of randomized controlled trials. J Cardiac Fail 2011; 17: 850–9 CrossRef MEDLINE|
|17.||Felker GM, Lee KL, Bull DA, et al.: Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797–805 CrossRef MEDLINE PubMed Central|
|18.||Ellison DH: Diuretic therapy and resistance in congestive heart failure. Cardiology 2001; 96: 132–43 CrossRef|
|19.||Jentzer JC, DeWald TA, Hernandez AF: Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56: 1527–34 CrossRef MEDLINE|
|20.||Ronco C, Cicoira M, McCullough PA: Cardiorenal syndrome type 1. J Am Coll Cardiol 2012; 60: 1031–42 CrossRef MEDLINE|
|21.||Schwenger V, Remppis BA, Westenfeld R, et al.: Dialyse- und Ultrafiltrationsverfahren bei kardiorenalem Syndrom. Kardiologe 2014; 8: 26–35 CrossRef|
|22.||Constanzo MR, Guglin ME, Saltzberg MT, et al.: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 675–83 CrossRef MEDLINE|
|23.||Bart BA, Goldsmith SR, Lee KL, et al.: Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296–304 CrossRef MEDLINE PubMed Central|
|24.||Metra M, Davison B, Bettari L, et al.: Is worsening renal function an ominous prognostic sign in patients with acute heart failure? Circ Heart Fail 2012; 5: 54–62 CrossRef CrossRef MEDLINE|
|25.||Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP: Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010; 122: 265–72 CrossRef MEDLINE PubMed Central|
|26.||Cotter G, Metzkor E, Kaluski E, et al.: Randomized trial of high-dose isosorbide dinitrat plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrat in severe pulmonary oedema. Lancet 1998; 351: 389–93 CrossRef|
|27.||Abraham WT, Adams KF, Fonarow GC, et al.: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57–64 CrossRef MEDLINE|
|28.||Packer M, Colucci W, Fisher L, et al.: Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. J Am Coll Cardiol HF 2013; 1: 103–11 CrossRef|
|29.||Mebazaa A, Nieminen MS, Packer M, et al.: Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007; 297: 1883–91 CrossRef MEDLINE|
|30.||Landoni G, Biondi-Zoccai G, Greco M, et al.: Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 2012; 40: 634–46 CrossRefMEDLINE|
|31.||Thiele H, Zeymer U, Neumann FJ, et al.: Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367: 1287–96 CrossRef MEDLINE|
|32.||Shah SJ, Blair JEA, Filippatos GS, et al.: Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: Results from the hemodynamic, echocardiographic, and neurohormonal effects of Istaroxime, a novel intravenous inotropic and lusitropic agent: a Randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) Trial. Am Heart J 2009; 157: 1035–41 CrossRef MEDLINE|
|33.||Massie BM, O´Connor CM, Metra M, et al.: Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363: 1419–28 CrossRef MEDLINE|
|34.||O´Connor CM, Starling RC, Hernandez AF, et al.: Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32–43 CrossRef MEDLINE|
|35.||McMurray JJ, Teerlink, JR, Cotter G, et al.: Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007; 298: 2009–19 CrossRef MEDLINE|
|36.||Konstam MA, Gheorghiade M, Burnett JC, et al.: Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA 2007; 297: 1319–31 CrossRef MEDLINE|
|37.||Teerlink JR, Cotter G, Davison BA, et al.: Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381: 29–39 CrossRef|
|38.||Erdmann E, Semigran MJ, Nieminen MS, et al.: Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 2013; 34: 57–67 CrossRef MEDLINE|
|39.||Mitrovic V, Seferovic PM, Simeunovic D, et al.: Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006; 27: 2823–32 CrossRef MEDLINE|
|40.||Ponikowski P, Mitrovic V, Ruda M, et al.: A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 2014; 35: 431–41 CrossRef MEDLINE PubMed Central|
|e1.||Yusuf PJ, Rousseau, MF, Ahn SA, Bangdiwala SI: Effect of enalapril on 12 year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361: 1843–8 CrossRef|
|e2.||Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Eng J Med 1999; 341: 709–17 CrossRef MEDLINE|
|e3.||Zannad F, McMurray JJ, Krum H, et al.: Eplerenone in patients with systolic heart failure and mild symptoms. N Eng J Med 2011; 364: 11–21 CrossRef MEDLINE|
|e4.||Swedberg K, Komajda M, Bohm M, et al.: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet 2010; 376: 875–85 CrossRef CrossRef|
|e5.||Bardy GH, Lee KL, Mark DB, et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225–37 CrossRef MEDLINE|
|e6.||Cleland JG, Daubert JC, Erdmann E, et al.: Long-term effects of cardiac resynchronization therapy on mortality in heart failure. Eur Heart J 2006; 27: 1928–32 CrossRef MEDLINE|
|e7.||Dickstein K, Cohen-Solal A, Filippatos G, et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388–442 MEDLINE|
|e8.||Hummel A, Empen K, Dörr M, Felix SB: Diagnostik der systolischen und diastolischen Herzinsuffizienz. Internist 2014; 55: 647–54 CrossRef MEDLINE|
|e9.||Kociol RB, Horton JR, Fonarow GC, et al.: Admission, discharge, or change in B-Type Natriuretic Peptide and Long-Term Outcomes. Circ Heart Fail 2011; 4: 628–36 CrossRef MEDLINE PubMed Central|
|e10.||Michtalik HJ, Yeh H, Cambell CY, et al.: Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol 2011; 107: 1191–5 CrossRef MEDLINE|
|e11.||Masip J, Roque M, Sanchez B, Fernandez R, Subirana M, Exposito JA: Noninvasive ventilation in acute cardiogenic pulmonary edema. JAMA 2005; 294: 3124–30 CrossRef MEDLINE|
|e12.||Rossi GP, Calo LA, Maiolino G, Zoccali C: Ultrafiltration for the treatment of congestion: a window into the lung for a better caress to the heart. Nephrol Dial Transplant 2014; 29: 1335–41 CrossRef MEDLINE|
|e13.||Cuffe MS, Califf RM, Adams KF, et al.: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541–7 CrossRef MEDLINE|
|e14.||Werdan K, Ruß M, Buerke M, Delle-Karth G, Geppert A, Schöndube FA: Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment. Dtsch Arztebl Int 2012; 109: 343–51 VOLLTEXT|
Deutsches Aerzteblatt Online, 201610.3238/arztebl.2016.0039a
Deutsches Aerzteblatt Online, 201610.3238/arztebl.2016.0834
Deutsches Aerzteblatt Online, 201610.3238/arztebl.2016.0040
Deutsches Aerzteblatt Online, 201610.3238/arztebl.2016.0039c
Deutsches Aerzteblatt Online, 201610.3238/arztebl.2016.0039b
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, 202010.36106/ijsr/9724069
Journal of Cardiology & Current Research, 201810.15406/jccr.2018.11.00363
Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?Cardiac Failure Review, 202110.15420/cfr.2020.20